WHIPPANY, N.J., Nov. 24, 2015 /PRNewswire/ -- A new survey sponsored by Bayer revealed that many physicians report a lack of familiarity with chronic thromboembolic pulmonary hypertension (CTEPH).1 The survey was released today to bring attention to the condition and the need for further education to improve the patient pathway to diagnosis and effective treatment.
CTEPH is a rare, life-threatening form of pulmonary hypertension (PH) that causes high blood pressure in the lungs and can lead to right heart failure and death.2,3 Each year, in the US, about 600,000 persons have an acute pulmonary embolism, and it is estimated that there are between 500 and 2500 new cases of CTEPH diagnosed each year. The incidence and prevalence of CTEPH are yet to be accurately determined and may be significantly underestimated.4 In fact, as many as 1 out of every 25 people who had a pulmonary embolism (even if they were treated with at least 3 months of anticoagulants), go on to develop CTEPH.*
"Because surgery can be an effective treatment for CTEPH, it is critical that physicians suspect and diagnose the condition. Unfortunately, as demonstrated by this survey, recognition of CTEPH among primary care physicians is inadequate," said Richard Channick, M.D., director of Massachusetts General Hospital's Pulmonary Hypertension and Thromboendarterectomy Program. "We very much need further education to identify and treat these patients as quickly as possible."
The survey of 604 PCPs, cardiologists and pulmonologists (approximately 200 from each group) was conducted online by Schlesinger Associates from August 10, 2015 to August 18, 2015.
Additional findings illustrate that:
- Additional education on the preferred diagnostic test to identify CTEPH is needed.1 Symptoms of CTEPH can include shortness of breath, fatigue, light-headedness, fainting and chest discomfort.3 Because these symptoms are nonspecific, CTEPH is underdiagnosed and often misdiagnosed.4 A ventilation/perfusion (VQ) scan is the preferred test for screening for chronic thromboembolic disease, and it should be viewed as an initial step in the diagnosis of CTEPH,6 but 38 percent of cardiologists and pulmonologists surveyed did not know that it is the preferred screening test for CTEPH.5,6
- There is substantial under-recognition of surgery as a potential cure for CTEPH.1 The standard and potentially curative treatment for CTEPH is pulmonary thromboendarterectomy (PTE), in which blood vessels of the lungs are cleared of clot and scar material.6 More medical centers have begun performing PTE surgeries, and outcomes are improving6, but the number of physicians who recognize PTE as an option to cure CTEPH remains low – 20 percent of PCPs, 43 percent of cardiologists and 64 percent of pulmonologists.1 Although surgery is the most effective therapy for CTEPH3, 7, 50 percent of PCPs would categorize it as a last resort, rather than a cure (14 percent) or treatment (33 percent).8
- There is a lack of awareness of the connection between pulmonary embolism and CTEPH.1 Pulmonary embolism (PE) is a sudden blockage in a lung artery, which is usually caused by a blood clot that travels from a vein in the leg to the lung.1 CTEPH is one of five types of PH designated by the World Health Organization as Group 4. Diagnosis of CTEPH requires an appropriate diagnostic workup. The diagnosis of CTEPH is critical, as it is a potentially curable form of PH 1,6. As many as 1 out of every 25 previously treated patients with PE could develop CTEPH.4, According to the survey results, 82 percent of specialists feel general practitioners should refer patients with a PE to them immediately, but only 45 percent of PCPs surveyed said they would.1
- Specialists wish PCPs would refer patients with lung disease symptoms, including those of CTEPH, to them sooner.1 More than half (55 percent) of cardiologists and pulmonologists surveyed wish that general practitioners would better understand the specific signs and symptoms of CTEPH and pulmonary arterial hypertension (PAH), so that they can see patients sooner.
"Together with treating physicians, our goal is always to find ways to raise awareness about this misunderstood disease," said Dario Mirski, M.D., vice president and head, U.S. medical affairs at Bayer. "For patients with CTEPH, the benefits of surgery may be very positive, and we hope the results of this survey help drive conversations about optimal diagnostic tools and treatment among physicians and the patient community."
About the Physician Survey
The insights and findings represented above are based on a 2015 online survey conducted by Schlesinger Associates and sponsored by Bayer HealthCare. The survey was fielded from August 10, 2015 to August 18, 2015 among 202 PCPs, 202 cardiologists and 200 pulmonologists. For the survey, internal medicine physicians, family medicine physicians and general practitioners were considered PCPs. The survey has a margin of error at the 95 percent confidence level of +/-4.0 percent at the total level and +/-6.9 percent at the individual doctor level.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their lives. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
Intended for U.S. Media Only
Forward Looking Statement
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
* Based on a study with 223 patients in which approximately 4% were diagnosed with CTEPH within 2 years of their first episode of pulmonary embolism (blood clot in the lung). CTEPH did not develop after two years in any of the remaining patients.
1 Bayer PH Physician Survey, 2015. Data on file.
2 Pepke-Zaba et al. Chronic Thromboembolic pulmonary hypertension: role of medical therapy. ERS 2010.
3 Piazza G and Goldhaber SZ. N Engl J Med. 2011;364:351-360.
4 Tapson V et al. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc. 2006;3:564-7.
5 Kim et al. Chronic Thromboembolic Pulmonary Hypertension. J Am Coll Cardiol 2013; 62: D92-9.
6 Simonneau G, et al. J Am Coll Cardiol. 2009;54(suppl 1):S43-S54.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/physician-survey-demonstrates-need-for-greater-awareness-of-rare-life-threatening-lung-condition-300183883.html
SOURCE Bayer HealthCare